Newsroom
Inflammatix in the news
Immune cell ‘signatures’ could help guide treatment for critically ill patients
September 30, 2025
TriVerity Test Demonstrates High Accuracy in Differentiating Bacterial Versus Viral Infections
July 24, 2025
FDA clears acute infection and sepsis test
May 6, 2025
Recognizing It Early While Getting It Right: The Value of Novel Sepsis Testing Tools
April 2, 2025
A better, faster sepsis test that can save lives
February 6, 2025
Inflammatix Gets FDA Clearance for 30-Minute Sepsis Test, Preps for US Launch
January 21, 2025
Inflammatix Scores FDA Approval for Precision Infection Test
January 21, 2025
Inflammatix begins trial evaluating mRNA test for patient infection status
November 12, 2024
Press releases
September 12, 2024
Inflammatix Secures $57 Million to Advance Novel Diagnostic for Patients with Suspected Infections or Sepsis
November 28, 2023
Inflammatix Receives Breakthrough Device Designation from FDA for TriVerity™ Acute Infection and Sepsis Test System
November 15, 2023
Inflammatix Completes Technical Development for TriVerity™ Acute Infection and Sepsis Test System
September 13, 2023
UMCG and Inflammatix Collaborate to Improve Early Recognition and Clinical Decision Support for Sepsis Care
July 10, 2023
Inflammatix Appoints Heiner Dreismann as New Board Member
June 15, 2022
Inflammatix Appoints Dr. Purvesh Khatri as Chief Scientific Officer
November 30, 2021
Inflammatix Appoints Dr. Kian Beyzavi as New Board Member
November 18, 2021
Inflammatix Announces Additional $12.1 Million Funding from BARDA for ViraBac EZ Acute Infection Test
Machine learning blogs
Podcasts
Diagnosing Infection with Ljubomir Buturovic from Inflammatix
December 2023
Advances in Sepsis Diagnostics: the HostDx Sepsis Platform
May 2018